ADAG ▲ +0.6% - Adagene Inc.
$ADAG - Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
Adagene achieved a development milestone in its collaboration with Exelixis on SAFEbody® antibody-drug conjugate candidates, moving the stock up 0.6% today. Milestone achievements in drug development partnerships typically signal progress toward potential future revenue and validate the platform technology underlying the collaboration.
09-SEP-2026 08:00 AM ET
Share this post
More filings for $ADAG
ADAG - Adagene Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026#ADAG-SEC-Update-(08-JUN-2026)-ThinkSabio-Stocks Simplified)Jun 8, 2026
View full $ADAG filing history →💬 Comments
Loading comments…
Leave a comment
